MERIDIAN BIOSCIENCE INC (VIVO) Stock Price, Quote, News and Overview
NASDAQ:VIVO - Nasdaq - US5895841014 - Common Stock - Currency: USD
VIVO Quote, Performance and Key Statistics
33.97
0 (0%)
The current stock price of VIVO is 33.97 USD. In the past month the price increased by 2.26%. In the past year, price increased by 41.66%.
VIVO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ALC | ALCON INC | 29.9 | 45.13B | ||
| COO | COOPER COS INC/THE | 23.91 | 17.66B | ||
| ALGN | ALIGN TECHNOLOGY INC | 20.39 | 14.22B | ||
| SOLV | SOLVENTUM CORP | 17.55 | 12.61B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 30.7 | 6.01B | ||
| BLCO | BAUSCH + LOMB CORP | 25.4 | 5.55B | ||
| LNTH | LANTHEUS HOLDINGS INC | 11.27 | 5.44B | ||
| ICUI | ICU MEDICAL INC | 27.69 | 3.85B | ||
| XRAY | DENTSPLY SIRONA INC | 10.14 | 3.73B | ||
| HAE | HAEMONETICS CORP/MASS | 14.9 | 3.17B | ||
| NEOG | NEOGEN CORP | 25.1 | 2.18B | ||
| UFPT | UFP TECHNOLOGIES INC | 36.31 | 1.95B |
Related stock screener links
About VIVO
Company Profile
Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. The company is headquartered in Cincinnati, Ohio and currently employs 770 full-time employees. The firm is engaged in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, specialized polymerase chain reaction (PCR) master mixes, and bioresearch reagents used by other diagnostic test manufacturers and researchers in immunological and molecular tests for human, animal, plant and environmental applications. The firm's segments include Diagnostics and Life Science. The Diagnostics segment consists of manufacturing operations for infectious disease products in Cincinnati, Ohio; Quebec City, Canada; and Modi'in, Israel. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; and Luckenwalde, Germany.
Company Info
MERIDIAN BIOSCIENCE INC
3471 River Hills Dr
Cincinnati OHIO 45244 US
CEO: Jack Kenny
Employees: 770
Company Website: https://www.meridianbioscience.com/
Phone: 15132713700.0
MERIDIAN BIOSCIENCE INC / VIVO FAQ
What is the stock price of MERIDIAN BIOSCIENCE INC today?
The current stock price of VIVO is 33.97 USD.
What is the ticker symbol for MERIDIAN BIOSCIENCE INC stock?
The exchange symbol of MERIDIAN BIOSCIENCE INC is VIVO and it is listed on the Nasdaq exchange.
On which exchange is VIVO stock listed?
VIVO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MERIDIAN BIOSCIENCE INC stock?
6 analysts have analysed VIVO and the average price target is 34.68 USD. This implies a price increase of 2.09% is expected in the next year compared to the current price of 33.97. Check the MERIDIAN BIOSCIENCE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MERIDIAN BIOSCIENCE INC worth?
MERIDIAN BIOSCIENCE INC (VIVO) has a market capitalization of 1.49B USD. This makes VIVO a Small Cap stock.
How many employees does MERIDIAN BIOSCIENCE INC have?
MERIDIAN BIOSCIENCE INC (VIVO) currently has 770 employees.
What are the support and resistance levels for MERIDIAN BIOSCIENCE INC (VIVO) stock?
MERIDIAN BIOSCIENCE INC (VIVO) has a support level at 33.82 and a resistance level at 33.98. Check the full technical report for a detailed analysis of VIVO support and resistance levels.
Is MERIDIAN BIOSCIENCE INC (VIVO) expected to grow?
The Revenue of MERIDIAN BIOSCIENCE INC (VIVO) is expected to decline by -13.66% in the next year. Check the estimates tab for more information on the VIVO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy MERIDIAN BIOSCIENCE INC (VIVO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VIVO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VIVO, evaluating the profitability, health, valuation and growth aspects
- MERIDIAN BIOSCIENCE INC (VIVO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MERIDIAN BIOSCIENCE INC (VIVO) Sales and EPS estimates to see what analysts future expectations are.
- MERIDIAN BIOSCIENCE INC (VIVO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MERIDIAN BIOSCIENCE INC (VIVO) Insider and Institutional Ownership to learn about the owners and their transactions.
- MERIDIAN BIOSCIENCE INC (VIVO) Stock Chart to make your own analysis
- MERIDIAN BIOSCIENCE INC (VIVO) Latest news and press-releases to stay up to date.
Does MERIDIAN BIOSCIENCE INC (VIVO) stock pay dividends?
VIVO does not pay a dividend.
When does MERIDIAN BIOSCIENCE INC (VIVO) report earnings?
MERIDIAN BIOSCIENCE INC (VIVO) will report earnings on 2023-05-04, after the market close.
What is the Price/Earnings (PE) ratio of MERIDIAN BIOSCIENCE INC (VIVO)?
The PE ratio for MERIDIAN BIOSCIENCE INC (VIVO) is 24.62. This is based on the reported non-GAAP earnings per share of 1.38 and the current share price of 33.97 USD. Check the full fundamental report for a full analysis of the valuation metrics for VIVO.
VIVO Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to VIVO. When comparing the yearly performance of all stocks, VIVO is one of the better performing stocks in the market, outperforming 93.15% of all stocks.
VIVO Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to VIVO. While VIVO has a great health rating, its profitability is only average at the moment.
VIVO Financial Highlights
Over the last trailing twelve months VIVO reported a non-GAAP Earnings per Share(EPS) of 1.38. The EPS decreased by -17.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.75% | ||
| ROA | 9.17% | ||
| ROE | 11.54% | ||
| Debt/Equity | 0.07 |
VIVO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to VIVO. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of -39.02% and a revenue growth -13.66% for VIVO